Dr Gholamreza Hassanzadeh obtained his Ph.D. in 1998 in antibody engineering. In the late 90’s, he established the first examples of intrabody-mediated gene modulation in a whole organism from animal kingdom. After his Ph.D., he joined the VIB myeloid Cell immunology group where he devoted himself to the differential gene expression studies in cancer and inflammatory diseases with focus on therapeutic target discovery. His publications in this period described the first examples of genetic signatures of M2 macrophages as opposed to M1. Since 2006, he is the head of VIB Nanobody Core, a service facility dedicated to the development of Nanobody-based affinity reagents for research, diagnosis and therapy. He is also an independent consultant in the field of antibody therapeutics.